MOH
Molina Healthcare, Inc.
$210.20
+1.37% 2026-10-19
Health CareS&P 400
MOHSPY
1W
+2.9%
1M
+4.7%
3M
-8.5%
6M
+40.0%
YTD
+21.1%
1Y
+9.1%
Grades vs sector
Momentum56th pct in sectorC+
Momentum
56th pct in sector
12-1 return: +23.5%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth4th pct in sectorF
Growth
4th pct in sector
Revenue growth (YoY): -5.7%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value45th pct in sectorC
Value
45th pct in sector
Forward E/P: 4.7% · EBITDA/EV: 6.7%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability22nd pct in sectorD
Profitability
22nd pct in sector
Profit margin: -0.0% · Return on equity: -0.2%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap$11.0B
P/E (trailing)2,335.6
P/E (forward)21.6
52-week range121.06 – 244.89
Revenue growth (YoY, latest qtr)-5.7%
Dividend yield0.00%
Analyst consensusHold (17)
Mean price target$209.12 (-1%)
Valuation & fundamentals
Bottom line
Leans expensive
Model read-out from the numbers below, not advice. Score -1 (DCF counts double).
•DCF (base case)below the price by 6%
▼Forward P/E vs sector21.6x vs median 17.6x
•Piotroski F-score4/9
▲Altman Z4.1 (safe)
▲Net debt / EBITDA-13.9x
•Analyst target-1% (17 analysts)
Discounted cash flow
Bear
$159
-24%
growth -2% · disc. 9.2% · term. 2.0%
Base
$197
-6%
growth 3% · disc. 8.2% · term. 2.5%
Bull
$255
+21%
growth 6% · disc. 7.2% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 5% a year for 10 years.
Implied
+5%/yr
FCF, last 3 yrs
n/a
FCF, last 5 yrs
n/a
Revenue, last 3 yrs
+12%/yr
Revenue, last 5 yrs
+19%/yr
Same inputs as the DCF above: trailing free cash flow 0.3B, 8.2% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.78 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
pricier
sector median 29.9× · 100th pct
2,335.6×pricier
Forward P/E
pricier
sector median 17.6× · 66th pct
21.6×pricier
EV / EBITDA
cheaper
sector median 15.8× · 50th pct
15.7×cheaper
Price / sales
cheaper
sector median 3.1× · 2nd pct
0.2×cheaper
Price / book
cheaper
sector median 3.5× · 38th pct
2.6×cheaper
FCF yield
pricier
sector median 4.1% · 30th pct
2.5%pricier
Forward EPS $9.75 vs trailing $0.09 (+10728% expected growth). Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
RPO
$638.0M
as of 2018-06-30
vs a year ago
–
YoY
× TTM revenue
0.01×
coverage
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Gross margin
5.6%
Operating margin
0.5%
FCF margin
0.6%
Net margin
-0.0%
Return on equity
-0.2%
Return on invested capital
–
Net debt / EBITDA
-13.9×
Current ratio
1.7×
Interest cover
1.0×
Cash conversion (OCF/NI)
–
Piotroski F-score 4/9 · last two fiscal years
✓ Positive net income✗ Positive operating cash flow✗ Return on assets improved✗ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score 4.1 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$209
-1%
Analysts
17
Hold
Range
$147–$266
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $45.4B | $472.0M | $-636.0M |
| 2024 | $40.6B | $1.2B | $544.0M |
| 2023 | $34.1B | $1.1B | $1.6B |
| 2022 | $32.0B | $792.0M | $682.0M |
| 2021 | $27.8B | $659.0M | $2.0B |
| 2020 | $19.4B | $673.0M | $1.8B |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +12.4%.
Earnings
Next report: 2026-10-21 · after close · EPS est 0.79
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-22 | 1.40 | 1.51 | +7.8% |
| 2026-04-22 | 1.91 | 2.35 | +23.0% |
| 2026-02-05 | 0.33 | -2.75 | -921.5% |
| 2025-10-22 | 3.89 | 1.84 | -52.7% |
| 2025-07-23 | 5.53 | 5.48 | -0.9% |
| 2025-04-23 | 5.96 | 6.08 | +2.0% |
| 2025-02-05 | 5.88 | 5.05 | -14.2% |
| 2024-10-23 | 5.94 | 6.01 | +1.2% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $10.9B | -4.8% |
| 2026-03-31 | $10.8B | – |
| 2025-12-31 | $11.4B | – |
| 2025-09-30 | $11.5B | – |
| 2025-06-30 | $11.4B | – |
Analyst actions
Wells Fargo
PT $220
2026-07-28 · main
Equal-Weight → Equal-WeightPT $220
Truist Securities
PT $225
2026-07-24 · main
Hold → HoldPT $225
RBC Capital
PT $218
2026-07-24 · main
Sector Perform → Sector PerformPT $218
Barclays
PT $180
2026-07-24 · main
Underweight → UnderweightPT $180
TD Cowen
PT $230
2026-07-14 · main
Hold → HoldPT $230
Truist Securities
PT $250
2026-07-14 · main
Hold → HoldPT $250
Insider trades
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
News
UnitedHealth's Q3 Margins Improve, But Membership Falls: Time to Buy?
Zacks · Oct 16
Can Molina Healthcare Overcome Lower Premiums and Higher MCR in Q3?
Zacks · Oct 16
Oscar Health vs. Molina: Which Healthcare Stock Is a Better Buy?
Zacks · Oct 16
Why Healthcare Stocks Are Hot When the AI Trade Runs Cold
Barrons.com · Oct 15
3 US Managed Care Stocks Facing Election And Healthcare Cost Pressure
Simply Wall St. · Oct 15
Analysts Estimate Molina (MOH) to Report a Decline in Earnings: What to Look Out for
Zacks · Oct 14
Centene vs. Molina: Which Managed Care Stock Has More Upside?
Zacks · Oct 12
Salesforce upgraded, Adobe downgraded: Wall Street's top analyst calls
The Fly · Oct 12
Stats refreshed 2026-10-19 19:01:49 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau